undamentalytics Newsletter
Sign in

Ginkgo Bioworks Holdings, Inc. cash flow statement

In fiscal 2025, Ginkgo Bioworks Holdings, Inc.'s operations generated −$171m of cash; it spent $7.7m on capital projects, leaving free cash flow of −$179m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−45−136−254−252−296−320−171−170
Depreciation and amortisation1114294371635954
Stock-based pay101,6061,9312301128262
Capital spending22585752416385
Free cash flow−67−194−310−304−336−382−179−175
Free cash flow after stock pay−68−194−1,916−2,235−566−494−260−237
Share buybacks002500———
Shares issued—015400019—

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: DNA vs SPRYDNA vs RCUSDNA vs XNCR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Ginkgo Bioworks Holdings, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Ginkgo Bioworks Holdings, Inc.